Calculating the number needed to treat for trials where the outcome is time to an event
about
Associations between stroke mortality and weekend working by stroke specialist physicians and registered nurses: prospective multicentre cohort studyExtent of lymph node dissection for adenocarcinoma of the stomachSentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanomaSystemic treatments for metastatic cutaneous melanomaTrastuzumab containing regimens for early breast cancerSentinel lymph node biopsy followed by lymph node dissection for early cutaneous melanomaInterferon alpha for the adjuvant treatment of cutaneous melanomaRole of rituximab for first-line or relapsed aggressive B-cell lymphomaChemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphomaErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataInterferon-alpha for maintenance of follicular lymphomaLow protein diets for chronic kidney disease in non diabetic adultsChemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaLow protein diets for chronic kidney disease in non diabetic adultsProtocol for an overview of systematic reviews of interventions to reduce unscheduled hospital admissions among adultsCONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trialsExemestane for breast cancer prevention: a critical shift?Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.Analysis of occupational asbestos exposure and lung cancer mortality using the g formulaHigh Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD CohortSecond-line systemic therapy for metastatic colorectal cancer.Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial.An online spaced-education game among clinicians improves their patients' time to blood pressure control: a randomized controlled trial.Estimating the number needed to treat (NNT) index when the data are subject to error.Number needed to treat for time-to-event data with competing risks.Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials.An inadvertent but explicable error in calculating number needed to treat for reporting survival dataCalculation of NNTs in RCTs with time-to-event outcomes: a literature reviewEffect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review.Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials.Assessing Heterogeneity of Treatment Effects: Are Authors Misinterpreting Their Results?Outcomes of Treated Hypertension at Age 80 and Older: Cohort Analysis of 79,376 IndividualsUnintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch databaseDoes improving maternal knowledge of vaccines impact infant immunization rates? A community-based randomized-controlled trial in Karachi, PakistanDaily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.Empiric potassium supplementation and increased survival in users of loop diuretics.HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis.Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
P2860
Q21562280-818308E0-5EE6-44C3-BCFA-AE49D6BA234EQ24187911-069237C3-E4CD-4183-AB1E-9DA76088243DQ24187945-D6707F44-DCDA-43D2-AEC8-ACFEAE548DBBQ24194804-580AE735-9B24-4912-BA1F-CF2E7396DBA6Q24200192-7042F2ED-C134-473C-A1CA-E93B48B088ACQ24201860-20069679-1778-4FE3-9C38-3C940621A870Q24201908-280D363C-6B25-41B3-B824-18B0B20B9FBEQ24236580-1FBC5C42-D5D1-4700-9FBA-44870067A1BAQ24236589-D19E8728-1BEA-4F95-9071-1E8A25742192Q24240202-D4EF5C4E-7EB4-476E-B68F-BDBFA9DC32DDQ24240781-F9E12479-E0F6-43EA-A12D-949B21368F21Q24241756-4DE50E7C-8686-40E2-8C36-7AC9FA727519Q24243100-6CB51B9A-DAC6-45FF-8004-13EBA2176C57Q24246169-E4736F17-7F35-452D-8360-88F2D7B4F541Q24289036-A7E09FD1-626B-41B1-A80F-B2B98FEDEE03Q24614627-E07CEDB2-F14C-4D32-941D-BA43A8C116DBQ27028211-46B23959-2944-458B-844D-39B0B38AA67EQ27851630-C2EE8233-CD35-4556-BD0A-13BF4C085B2FQ28397492-54289AAB-6045-4B8D-84F2-850476B2A85CQ28550768-4B611202-2C5C-4363-87F9-9B261C239660Q30238760-F0C7BF15-9CB4-459E-BD20-43B7AD6405CBQ30276113-964AE64E-5B2B-420B-A76F-E99AB0A52B03Q30579393-C001B4EB-0FF8-4A09-981D-3F743BB8A658Q30639578-BD169376-9DF6-4123-BA40-CD111823FD3BQ30666984-D47F9830-EA32-45A9-BAE4-7733319FB1C8Q30789570-A7B71A8F-6097-4FF1-B980-7D8897AC0E96Q30798455-AAC8780B-AF47-466F-B106-63C1DA483E78Q30859793-40587847-D6E5-4A37-BE22-B6220FA5633EQ30871643-85FA6081-05C1-49A6-A18C-BE1C3CDDFE9EQ30937299-8E284C8A-C55D-4CAF-89D8-67A3018223E8Q31112168-4FF0E83D-B58E-4241-B1FC-EFEE5B364350Q33618795-4C2C013E-3440-4562-9AA5-684B9D77573DQ33834035-C64EEC65-29F4-4141-A657-2ABCAC322DF3Q33867311-6A6AF492-25E4-49D9-A39E-48148526A1CBQ33874517-8CAB0754-F844-44C6-87C4-9CB1B9BF77D7Q33881449-0F42C569-F571-422F-83AD-8CEB2C60823FQ33910812-EEB116E5-5A12-4B8D-B8E3-4FE10D44B0ABQ34046430-38ACAFDA-EE2B-44D8-8B56-D5EC646523DBQ34112745-14998856-35AD-4B51-A7CE-2BDDD94A45FCQ34158442-8C67249B-55A0-4721-A983-B3A862389F6C
P2860
Calculating the number needed to treat for trials where the outcome is time to an event
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Calculating the number needed to treat for trials where the outcome is time to an event
@ast
Calculating the number needed to treat for trials where the outcome is time to an event
@en
type
label
Calculating the number needed to treat for trials where the outcome is time to an event
@ast
Calculating the number needed to treat for trials where the outcome is time to an event
@en
prefLabel
Calculating the number needed to treat for trials where the outcome is time to an event
@ast
Calculating the number needed to treat for trials where the outcome is time to an event
@en
P2860
P1433
P1476
Calculating the number needed to treat for trials where the outcome is time to an event
@en
P2093
Andersen PK
P2860
P304
P356
10.1136/BMJ.319.7223.1492
P407
P577
1999-12-01T00:00:00Z